CONCARLO HOLDINGS, LLC

BROOKLYN, NY · CIK 0001701751 · Biotech · Private

IpY, a novel peptide-lipid therapeutic that targets p27Kip1 to inhibit both CDK4 and CDK2 for advanced ER/PR+, Her2- breast cancer

concarlo.com →
Grants
$320K
1 award
Sector median: 1
Raised
$450K
1 Form D · Mar 2017
115 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$450,000
Federal grantDepartment of Health and Human Services · Phase I · Developing IpY: A novel inhibitor for the treatment of ER+ metastatic breast cancer$320,217
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2602JumpStart Fertility, Inc.—$500K
2603ENFUEGO THERAPEUTICS, INC.—$500K
2604CHAPERONE THERAPEUTICS, INC.—$457K
2605CONCARLO HOLDINGS, LLC—$450K
2606GSNO THERAPEUTICS, INC.——
2607ANEURYST, INC.——
2608GABAeron, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • LisaMarie CaseyDirector · Executive Officer

Patents

USPTO · 0 granted of 3
  • Brk Peptides And Methods Of Useapplication
  • Brk Peptides And Methods Of Useapplication
  • Brk Peptides And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.